Seven weeks ago, retatrutide delivered 28.3% weight loss in TRIUMPH 1—the most effective weight loss data ever produced in a Phase 3 trial. This morning, Lilly reported that the same drug hit positive topline results in TRIUMPH 2, the type 2 diabetes trial, demonstrating both HbA1c reduction and weight loss in patients with T2D. Two pivotal wins in seven weeks. Two of the three indications Lilly needs for the broadest possible label. And five more TRIUMPH readouts still to come.
Retatrutide is a once weekly injectable that simultaneously activates three metabolic pathways: GIP, GLP 1, and glucagon. Every other approved obesity or diabetes drug targets one or two of those receptors. Retatrutide targets all three. The glucagon component is what produces the additional weight loss beyond what Zepbound can achieve—it increases energy expenditure and fat oxidation on top of the appetite suppression that GLP 1 and GIP provide. In obesity, that combination delivered results that match bariatric surgery. In diabetes, it is now confirmed to improve the blood sugar control that is the regulatory requirement for a T2D label.
An NDA filing is likely imminent if not already underway. BMO projects a 2027 launch. Truist estimated conservative worldwide peak sales of $12 billion to $19 billion. That was before the T2D data. With two pivotal indications now positive—obesity and diabetes—the addressable population roughly doubles from the approximately 40 million American adults with clinical obesity to include the approximately 37 million with type 2 diabetes. And the cardiovascular trial, TRIUMPH 3, is still reading out this year.
Separately, Vertex signed a $1.4 billion deal to expand in hereditary angioedema. J&J’s talquetamab hit Phase 3 in myeloma. And the Section 232 tariff deadline is 23 days away.
TRIUMPH 2: The Diabetes Label That Doubles the Market
What Happened: Lilly announced positive topline results from the Phase 3 TRIUMPH 2 trial evaluating retatrutide in adults with type 2 diabetes. The drug met primary and key secondary endpoints for HbA1c reduction and body weight reduction.
Why This Was the Expected Win That Still Matters Enormously
Nobody in the industry was surprised that retatrutide worked in diabetes. A drug that hits GLP 1 receptors (which is the mechanism behind every approved GLP 1 diabetes drug) was always going to lower blood sugar. The question was never if. The question was how much, with what safety profile, and how it compares to the existing drugs already dominating the diabetes market.
We will not know the specific HbA1c reduction numbers until Lilly presents the full data at a medical meeting, but the “positive topline” announcement confirming both endpoints tells us the drug cleared the regulatory bar. Given retatrutide’s 28.3% weight loss in obesity (versus Zepbound’s approximately 22% and Wegovy’s approximately 15 to 17%), the diabetes weight loss component is likely to show a similar magnitude advantage. In a disease where weight is one of the primary drivers of insulin resistance and disease progression, a drug that controls blood sugar and delivers the most weight loss of any pharmaceutical agent is a compelling proposition.
Lilly’s Three Tier Portfolio Is Now Two Thirds Validated at the Pivotal Level
Foundayo is approved for obesity and has a T2D filing submitted under CNPV. Zepbound is approved for obesity. And now retatrutide has two pivotal wins: obesity (TRIUMPH 1) and diabetes (TRIUMPH 2).
The three tier framework Lilly laid out earlier this year is coming together:
Foundayo (oral, approximately 12% weight loss, approved in obesity, T2D filing imminent): the convenience tier. No injections, no food restrictions, the easiest product for a patient to start.
Zepbound (injectable GIP/GLP 1, approximately 22% weight loss, approved in obesity): the established injectable standard. Strong clinical data, growing commercial franchise, Medicare Bridge coverage at $50 copay.
Retatrutide (injectable GIP/GLP 1/glucagon, 28.3% weight loss, two pivotal wins): the maximum efficacy tier. Bariatric surgery level results through a once weekly injection. Now confirmed in both obesity and diabetes. Cardiovascular trial still reading out.
No other company has three distinct products spanning oral convenience to maximum injectable efficacy across both obesity and diabetes. Novo has two versions of semaglutide (oral Wegovy and injectable Wegovy), but both deliver the same mechanism at the same approximate efficacy level. Lilly’s portfolio offers physicians a clinical decision tree: start with Foundayo for the patient who wants a pill, escalate to Zepbound if they need more weight loss, and move to retatrutide when they need the most aggressive pharmacological approach short of surgery.
The Filing Timeline
With two positive pivotal trials in hand (TRIUMPH 1 for obesity, TRIUMPH 2 for T2D), Lilly has the dataset to support an NDA that could include both indications from the start or could file for one and add the other as a supplemental application. BMO’s projected 2027 launch implies a filing in late 2026 or early 2027.
The CNPV program, if applied to retatrutide (as it was for Foundayo’s obesity approval in 50 days), could compress the review timeline substantially. But the CNPV’s capacity is being tested: Revolution’s daraxonrasib filing is imminent, Foundayo’s T2D application may already be in house, and the program is operating under acting leadership. Whether the FDA can process multiple high priority reviews simultaneously under these conditions remains the open question.
Our Pro brief models how the T2D label changes the peak sales trajectory, assesses where retatrutide fits in the $200B plus addressable market across obesity, diabetes, and cardiovascular disease, and evaluates the filing and launch timeline scenarios. [Details below.]
Vertex Signs $1.4B Deal for Hereditary Angioedema
What Happened: Vertex Pharmaceuticals agreed to acquire Pharming Group for up to $1.4 billion ($400 million upfront plus up to $1 billion in milestones) to gain a portfolio of hereditary angioedema treatments, including an approved C1 esterase inhibitor.
Vertex Is Building a Rare Disease Portfolio Beyond Cystic Fibrosis
Vertex has been the dominant company in cystic fibrosis for a decade, with Trikafta generating more than $8 billion in annual revenue. But the CF franchise, while durable, has a finite patient population. The company has been expanding into new therapeutic areas—pain (VX 548 sodium channel inhibitor), kidney disease (partnerships), and gene editing (Casgevy in sickle cell, expanded into younger children via CNPV last week).
The Pharming deal adds hereditary angioedema, a rare disease characterized by severe, unpredictable swelling episodes that can be life threatening when they affect the airway. The C1 esterase inhibitor that Pharming markets is a replacement therapy for the protein that patients with HAE lack. The market has multiple approved treatments from several companies (Takeda, BioCryst, others), but Vertex’s entry gives it a commercial rare disease asset that generates immediate revenue while the company develops its next generation pipeline.
For Vertex, the deal is less about transforming the company than about diversifying the revenue base. Every dollar of revenue from HAE is a dollar that does not depend on the CF franchise. As Vertex pushes into pain, kidney disease, sickle cell, and now HAE, it is evolving from a single franchise biotech into a multi therapeutic rare disease company—a transition that CFOs and analysts have been watching for years.
J&J’s Talquetamab Hits Phase 3 in Myeloma
What Happened: Johnson and Johnson reported positive Phase 3 results for talquetamab, a bispecific antibody targeting GPRC5D and CD3, in patients with relapsed or refractory multiple myeloma.
Why This Matters: Talquetamab is already approved for heavily pretreated myeloma under the brand name Talvey. The Phase 3 data in a broader myeloma population support label expansion into earlier treatment lines where patient populations are larger and treatment durations are longer.
The bispecific antibody class has been building momentum in myeloma throughout the year. J&J has Tecvayli (teclistamab, targeting BCMA and CD3) and now Talvey (talquetamab, targeting GPRC5D and CD3). Having two bispecifics with different targets allows J&J to offer sequential therapy—patients who progress on one target can switch to the other. That sequential strategy, combined with earlier line positioning through Phase 3 confirmatory data, gives J&J the most comprehensive bispecific myeloma franchise in the industry.
The myeloma treatment landscape continues to evolve rapidly. Lilly’s Kelonia in vivo CAR T program (which showed data at ASCO that “justified” the $3.2 billion acquisition) targets BCMA through a different modality. Gilead acquired Arcellx ($7.8 billion) for anito cel, also BCMA directed. The convergence of bispecific antibodies and CAR T therapies on the same disease, through different mechanisms and delivery approaches, is giving myeloma patients more options than they have ever had.
Teva and Scinai Sign ADC Research Collaboration
What Happened: Teva Pharmaceutical and Israeli biotech Scinai Immunotherapeutics signed an antibody drug conjugate research collaboration. Financial terms were not disclosed.
Why This Matters: Teva’s entry into the ADC space, even at the research level, adds another buyer to a modality that has attracted billions in investment this year. Teva is known primarily for generics and specialty pharmaceuticals rather than novel oncology development. An ADC collaboration signals the company is exploring ways to participate in one of the hottest areas in drug development, though at an early enough stage that the financial commitment is modest and the clinical risk is years away.
The deal also continues the pattern of ADC interest spreading beyond traditional oncology focused pharma. Merck has sac TMT. Gilead has its Tubulis platform. Lilly has CrossBridge. Novartis just paid $1.5 billion for Myricx’s ADC payload platform. And now Teva, a generics company, is exploring the space. The modality’s gravity is pulling in companies across the entire pharmaceutical spectrum.
Section 232 Tariffs: 23 Days and Counting
The Section 232 pharmaceutical tariff deadline for large companies is July 31. Twenty three days from today. For smaller companies, the deadline is September 29. The tariff framework imposes costs on imported pharmaceutical products and is designed to incentivize domestic U.S. manufacturing.
Companies have had months of warning, but the operational reality of restructuring global supply chains does not compress neatly into a timeline set by policy rather than logistics. Shifting manufacturing from overseas facilities to U.S. based production takes years, not months. Building new plants, securing regulatory approvals for new manufacturing sites, qualifying raw material suppliers, and scaling up production are all processes with their own irreducible timelines.
What companies can do in 23 days: finalize their tariff exposure calculations, confirm which products face the highest marginal cost increase, lock in inventory positions for products manufactured overseas, and prepare pricing and supply chain communications for customers. What they cannot do: fundamentally change where their drugs are made.
The tariff deadline lands alongside the Medicare Bridge (launched July 1), the MFN pricing framework (already in effect), and European pricing reforms (which prompted Lilly and Boehringer to pull more than $2 billion combined from Germany). The cumulative effect of these concurrent policy shifts on pharmaceutical economics is without modern precedent. Every company is navigating all of them simultaneously.
Strategic Themes
1. Two Pivotal Wins in Seven Weeks Makes Retatrutide the Most Validated Late Stage Drug in the Industry
28.3% weight loss in obesity. Positive HbA1c and weight loss in diabetes. Two of three target indications confirmed at the pivotal level. The cardiovascular trial is still coming. If TRIUMPH 3 is also positive, retatrutide will have the broadest clinical evidence package of any metabolic disease drug in history: obesity, diabetes, and cardiovascular risk reduction in a single molecule. The December 7 Investment Community Meeting will be the venue where Lilly frames the retatrutide franchise for investors and the Street. With two pivotal wins already in hand and the CV readout expected before year end, that presentation could be the most consequential in the company’s history.
2. Vertex’s HAE Deal Shows Even the Best Single Franchise Biotechs Need to Diversify
Trikafta generates more than $8 billion annually and dominates cystic fibrosis. But a single franchise, no matter how strong, creates concentration risk. The Pharming acquisition is not transformative in the way that a GSK/Nuvalent or AbbVie/Apogee deal is. It is pragmatic: add a commercial rare disease asset that generates revenue, reduces franchise concentration, and fits the rare disease infrastructure that Vertex is building across CF, sickle cell, pain, and kidney disease.
3. The ADC Space Has Reached Escape Velocity
Novartis paid $1.5 billion for a payload platform yesterday. Teva signed a research collaboration today. Merck’s sac TMT has two Phase 3 wins. Gilead deployed $15 billion in ADC related acquisitions. Daiichi Sankyo’s new R&D chief is trying to outrun the gold rush his company started. The modality has moved past the question of “does this work?” and into the question of “who has the best technology and which programs win?” When generics companies start exploring ADCs alongside the oncology focused pharma leaders, the space has reached a level of commercial credibility that attracts every kind of buyer.
4. The Section 232 Countdown Creates Real Operational Pressure in the Next Three Weeks
July 31 is not a distant policy concern. It is a supply chain deadline arriving in 23 days. Companies that have not finalized their tariff exposure, inventory positions, and pricing strategies are running out of time. The deadline lands on top of the Medicare Bridge (just launched), MFN pricing (in effect), and European reforms (compressing margins from the other side). The concurrent policy environment is creating a complexity burden on pharma operations teams that has no modern precedent.
Frequently Asked Questions
What did TRIUMPH 2 show?
Retatrutide met primary and key secondary endpoints for HbA1c reduction and weight loss in adults with type 2 diabetes. This is the second pivotal win in seven weeks after TRIUMPH 1 (28.3% weight loss in obesity). Full data will be presented at an upcoming medical meeting.
When could retatrutide be approved?
BMO projects a 2027 launch. An NDA filing is likely imminent or underway. If the CNPV program is applied, review could be accelerated. Five more TRIUMPH readouts are expected, including the cardiovascular trial (TRIUMPH 3).
What is the Vertex/Pharming deal?
Up to $1.4 billion ($400M upfront) for hereditary angioedema treatments including an approved C1 esterase inhibitor. Gives Vertex a commercial rare disease asset and diversifies the revenue base beyond cystic fibrosis.
What did J&J’s talquetamab show?
Positive Phase 3 data in relapsed/refractory multiple myeloma. Supports label expansion into broader patient populations. J&J now has two bispecific myeloma drugs (Tecvayli and Talvey) targeting different antigens for sequential therapy.
When do Section 232 tariffs take effect?
July 31 for large companies. September 29 for all others. Twenty three days from today for the first deadline. The tariff framework imposes costs on imported pharmaceutical products to incentivize domestic manufacturing.
How many TRIUMPH trials are there?
Eight total. TRIUMPH 1 (obesity, positive) and TRIUMPH 2 (T2D, positive) have reported. TRIUMPH 3 (cardiovascular disease) is the most commercially significant remaining trial. Additional trials cover sleep apnea, chronic low back pain, liver disease, and other indications.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
The Retatrutide Franchise. We model how the T2D win changes the peak sales trajectory, assess where retatrutide fits in the addressable market across obesity, diabetes, and cardiovascular disease, and evaluate the filing and launch timeline scenarios under standard NDA and CNPV review.
Vertex Beyond CF. We analyze why the Pharming HAE deal matters for franchise diversification, map Vertex’s expanding rare disease portfolio (CF, sickle cell, pain, kidney, HAE), and assess how the company’s transition from single franchise to multi therapeutic platform is progressing.
Section 232 Countdown. We detail which product categories face the highest tariff exposure, which companies have the most overseas manufacturing dependency, and what operational steps are still possible in the 23 days before the deadline.
Plus: J&J myeloma bispecific franchise analysis, Teva ADC entry, retatrutide vs Foundayo T2D positioning, Revolution filing watch, and the full H2 catalyst calendar.
About BioMed Nexus
BioMed Nexus delivers institutional grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep dive analyses cut through the noise to deliver the strategic insights that drive better decision making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
